Loading organizations...
Vector Laboratories, Inc. develops and manufactures a comprehensive portfolio of labeling and detection reagents integral to life science research. The company provides a range of products including antibodies, kits, and reagents that are critical for applications such as immunohistochemistry, immunofluorescence, and glycobiology, enabling scientists to detect and visualize biological structures and processes with high precision. Their offerings support various research workflows by providing essential tools for cellular and molecular analysis.
Established in 1976, Vector Laboratories has nearly five decades of experience serving the scientific community. The initial insight centered on the growing need for specialized, high-quality reagents to advance biological understanding and accelerate discovery in research laboratories. While specific founders are not detailed in available information, the company quickly positioned itself as a trusted partner in providing essential laboratory consumables, growing its product lines to meet evolving scientific demands.
Vector Laboratories primarily serves the global scientific community, including academic institutions, pharmaceutical companies, and biotechnology firms. Researchers rely on their products to conduct fundamental studies and develop new therapies. The company's vision is to remain a leading partner in science, consistently delivering innovative reagents that elevate experimental capabilities and drive progress in biological and medical research worldwide.
Key people at Vector Laboratories, Inc..
Vector Laboratories, Inc. was founded in 1978 by Dr. Jim Whitehead (Founder).
Key people at Vector Laboratories, Inc..
Vector Laboratories, Inc. is a biotechnology company founded in 1976 that develops and manufactures innovative reagents and kits for proteomic and glycomic research, serving academic, industrial, and manufacturing scientists worldwide.[1][2][4] It pioneered avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence, offering over 600 products including those for immunofluorescence, immunohistochemistry, glycobiology, bioconjugation, and custom manufacturing solutions.[1][2] With approximately 99 employees and $21.2 million in revenue, the company targets challenges in cancer research, neuroscience, immunology, and infectious diseases, empowering advances through reliable tools cited in over 350,000 peer-reviewed publications.[1][2][4]
Headquartered in Newark, California, Vector Laboratories supports global researchers via labs and offices in the US, UK, and Europe, bolstered by strategic acquisitions like Click Chemistry Tools, Fluoroprobes, Quanta BioDesign, and a merger with Absolute Biotech to expand its antibody-centric and high-performance offerings.[2][4]
Vector Laboratories was established in 1976 as a pioneer in scientific tools, initially focusing on immunohistochemistry before expanding into labeling, detection, conjugating technologies, immunofluorescence, and glycobiology.[1][2] The company quickly innovated by becoming the first to commercialize avidin-biotin enzyme complex kits and antifade mounting media, building a reputation over nearly five decades as a trusted partner with unmatched technical expertise.[1][2]
Key milestones include strategic acquisitions—Click Chemistry Tools, Fluoroprobes, and Quanta BioDesign—and a recent merger with Absolute Biotech, which broadened its portfolio for life sciences tools, diagnostics, and biotherapeutics.[2][4] This evolution reflects a commitment to growth while maintaining a culture of integrity, excellence, inclusion, and customer relationships, now supporting worldwide scientific industries from its Newark base.[1][2]
Vector Laboratories rides the wave of advancing proteomics, glycomics, and bioconjugation trends critical to precision medicine, including antibody-drug conjugates (ADCs) for targeted cancer therapies and tools for neuroscience and infectious disease research.[2] Its timing aligns with booming demand for high-fidelity reagents in diagnostics, biotherapeutics, and clinical research, fueled by market forces like rising R&D in immunotherapy and personalized medicine.[1][2][4]
The company influences the ecosystem by enabling reproducible results in peer-reviewed studies and SOPs worldwide, accelerating discoveries through custom solutions and acquisitions that fill gaps in labeling/detection tech.[1][2] As a manufacturing partner, it supports the life sciences supply chain, reducing barriers for researchers tackling complex diseases.[4]
Vector Laboratories is poised for continued expansion through its merger-enhanced portfolio, focusing on ADC research, bioconjugates, and custom reagents amid surging biotech innovation.[2][4] Trends like AI-driven drug discovery and federated learning in healthcare (though not core to Vector) will amplify demand for its precise proteomic tools, potentially driving revenue growth beyond $21M via global partnerships.[1][2]
Its influence may evolve as a comprehensive supplier in the biotherapeutics pipeline, solidifying leadership in immunofluorescence and glycobiology while adapting to sustainable manufacturing needs—ultimately empowering more breakthroughs from its foundational mission of scientific curiosity.[1][2][4]
Vector Laboratories, Inc. was founded in 1978 by Dr. Jim Whitehead (Founder).
